A5023507108- Cutaneous lymphoproliferative disorders research
- Cutaneous Melanoma Detection and Management
- Nonmelanoma Skin Cancer Studies
- Melanoma and MAPK Pathways
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Fungal Infections and Studies
- Asthma and respiratory diseases
- Nail Diseases and Treatments
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Hidradenitis Suppurativa and Treatments
- Mast cells and histamine
- Microscopic Colitis
- Skin Protection and Aging
- Autoimmune and Inflammatory Disorders
- Dermatological and COVID-19 studies
- Colorectal and Anal Carcinomas
- Cancer and Skin Lesions
- melanin and skin pigmentation
- Cancer Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
University of Turin
2021-2025
Oxfam
2023
Liechtenstein Institute
2023
John Wiley & Sons (United States)
2023
Hudson Institute
2023
John Wiley & Sons (United Kingdom)
2023
Pustular and erythrodermic psoriasis are rare difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential IL-23 is largely unknown. The aim this multicentre, retrospective study was to compare safety, effectiveness, drug survival IL-17 affected by psoriasis. involved 27 59 pustular (36 generalised 23 palmoplantar psoriasis) treated an or inhibitor. effectiveness two...
There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy in large populations required.
Introduction Over the past two years, scientific community has witnessed an exponential growth in research focused on identifying prognostic biomarkers for melanoma, both pre-clinical and clinical settings. This surge studies reflects need of developing effective indicators field melanoma.
In the last years, adalimumab biosimilars have represented a commonly used alternative to originator agent in treatment of moderate severe hidradenitis suppurativa. As today, studies investigating switch from biosimilar, following pharmacoeconomic policies, are lacking. Herein we present real-life setting retrospective study aimed at assessing safety and efficacy this 37 patients, evaluated for 12 months terms IHS4 (International Hidradenitis Suppurativa Severity Score System) HiSCR...
Incidence of cutaneous melanoma is steadily growing, and its early recognition paramount importance. Small, pigmented lesions often represent a challenge for the clinician, as predictors have not yet been uniquely identified in this setting.To identify dermoscopic features that aid distinguishing small diameter melanomas (≤5 mm) from equivocal melanocytic nevi measuring ≤5 mm.A retrospective multicenter study was conducted to collect demographics, clinical pictures (i) histology-proven flat...
This study was carried out at the Dermatologic Clinic of University Turin, Italy, to assess effectiveness and safety adjuvant therapy in patients who received either targeted (TT: dabrafenib + trametinib) or immunotherapy (IT: nivolumab pembrolizumab) for up 12 months. A total 163 participated, including 147 with stage III 19 IV no evidence disease. The primary outcomes were relapse-free survival (RFS), distant metastasis-free (DMFS), overall (OS). At 48 months, both TT IT approaches yielded...
Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking.To delineate a comprehensive view on how entity defined managed clinical practice; to evaluate whether current positioning plaques TNMB adequate.A 12-item survey was circulated within selected panel 22 experts (pathologists, dermatologists, haematologists oncologists), members EORTC International Society for Cutaneous Lymphoma. The questionnaire discussed histopathological definitions its...
Introduction Psoriasis affecting the genital, palmoplantar, and scalp regions is recognized as difficult-to-treat, data on efficacy of biologics in these areas remains limited.Research design methods This single-center study evaluated effectiveness anti-IL-17 anti-IL-23 agents scalp, palmoplantar psoriasis. We retrospectively analyzed from all patients with psoriasis being treated IL inhibitors at our clinic. Effectiveness was 16, 28, 52 weeks, according to achievement relative mean PSSI,...
Immunomodulating therapies harness the power of immune system to combat disease. In advanced melanoma, checkpoint inhibitors have significantly improved survival outcomes by activating recognize and eliminate cancer cells. psoriasis, interleukin effectively suppress inflammation improve disease symptoms.
Over the past decade, significant advancements in field of melanoma have included introduction a new staging system and development immunotherapy targeted therapies, leading to changes substage classification impacting patient prognosis. Despite these strides, early detection remains paramount. The quest for dependable prognostic biomarkers is ongoing, given melanoma's unpredictable nature, especially identifying patients at risk relapse. Reliable are critical informed treatment decisions.